Literature DB >> 21227512

Cyclosporine A affects the in vitro expression of T cell activation-related molecules and cytokines in dogs.

C L Fellman1, J V Stokes, T M Archer, L M Pinchuk, K V Lunsford, A J Mackin.   

Abstract

Cyclosporine is a powerful immunosuppressive drug that is being used with increasing frequency to treat a wide range of immune-mediated diseases in the dog. To date, ideal dosing protocols that will achieve immunosuppression with cyclosporine in dogs remain unclear, and standard methods that can measure effectiveness of immunosuppression have not been established. The aim of our study was to evaluate the effects of in vitro cyclosporine exposure on a panel of molecules expressed by activated T cells to ascertain their potential as biomarkers of immunosuppression in dogs. Blood was drawn from six healthy dogs, and peripheral blood mononuclear cells (PBMC) were isolated and activated. Half of the cells were incubated with 200 ng/mL cyclosporine prior to activation, and the other half were not exposed to cyclosporine. Samples were analyzed using flow cytometry, and the expression of intracellular cytokines IL-2, IL-4, and IFN-γ was evaluated after 6, 12, and 24h of drug exposure. Each cytokine exhibited a time-dependent suppression profile, and all but two samples activated in the presence of cyclosporine showed lower cytokine expression than untreated controls. We also evaluated the expression of the surface T cell activation molecules CD25 and CD95 by flow cytometry after 36 h of drug exposure. Expression of these surface molecules decreased significantly when activated in the presence of cyclosporine. Our results suggest that suppressed expression of the markers related to T cell activation could potentially be utilized as an indicator of the efficacy of cyclosporine therapy in dogs. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21227512     DOI: 10.1016/j.vetimm.2010.11.005

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  16 in total

1.  In-vitro immunosuppression of canine T-lymphocyte-specific proliferation with dexamethasone, cyclosporine, and the active metabolites of azathioprine and leflunomide in a flow-cytometric assay.

Authors:  Laura A Nafe; John R Dodam; Carol R Reinero
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

2.  Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation.

Authors:  Paige M Kulling; Kristine C Olson; Thomas L Olson; Cait E Hamele; Kathryn N Carter; David J Feith; Thomas P Loughran
Journal:  J Steroid Biochem Mol Biol       Date:  2017-07-20       Impact factor: 4.292

3.  Chemokine receptor 7 (CCR7)-expression and IFNγ production define vaccine-specific canine T-cell subsets.

Authors:  Ashley N Hartley; Rick L Tarleton
Journal:  Vet Immunol Immunopathol       Date:  2015-02-07       Impact factor: 2.046

4.  Pharmacodynamic assessment of ex-vivo canine T-lymphocyte proliferation: Responses to dexamethasone, cyclosporine, mycophenolic acid, and the active metabolite of leflunomide.

Authors:  Megan Grobman; Kaitlin A Bishop; Hansjorg Rindt; Laura A Nafe; Carol R Reinero
Journal:  Can J Vet Res       Date:  2019-10       Impact factor: 1.310

5.  Pharmacokinetic evaluation of oral dantrolene in the dog.

Authors:  J L Haraschak; V C Langston; R Wang; C Riggs; C Fellman; M K Ross; C Bulla; K Lunsford; A Mackin; T Archer
Journal:  J Vet Pharmacol Ther       Date:  2013-11-13       Impact factor: 1.786

6.  Analytical validation of a quantitative reverse transcriptase polymerase chain reaction assay for evaluation of T-cell targeted immunosuppressive therapy in the dog.

Authors:  C Riggs; T Archer; C Fellman; A S Figueiredo; J Follows; J Stokes; R Wills; A Mackin; C Bulla
Journal:  Vet Immunol Immunopathol       Date:  2013-12-15       Impact factor: 2.046

7.  Effects of oral cyclosporine on canine T-cell expression of IL-2 and IFN-gamma across a 12-h dosing interval.

Authors:  C L Fellman; T M Archer; J V Stokes; R W Wills; K V Lunsford; A J Mackin
Journal:  J Vet Pharmacol Ther       Date:  2015-12-17       Impact factor: 1.786

Review 8.  Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis.

Authors:  Tim Nuttall; Douglas Reece; Elizabeth Roberts
Journal:  Vet Rec       Date:  2014-03       Impact factor: 2.695

9.  Unsuccessful cyclosporine plus prednisolone therapy for autoimmune meningoencephalitis in three dogs.

Authors:  Dong-In Jung; Hee-Chun Lee; Jeongim Ha; Hae-Won Jung; Joon-Hyeok Jeon; Jong-Hyun Moon; Jae-Hoon Lee; Na-Hyun Kim; Jung-Hyang Sur; Byeong-Teck Kang; Kyu-Woan Cho
Journal:  J Vet Med Sci       Date:  2013-08-13       Impact factor: 1.267

Review 10.  Oral cyclosporine treatment in dogs: a review of the literature.

Authors:  T M Archer; D M Boothe; V C Langston; C L Fellman; K V Lunsford; A J Mackin
Journal:  J Vet Intern Med       Date:  2013-12-16       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.